GSK’s Breo Breathing A Little Easier In Asthma, But More Studies Ahead
This article was originally published in The Pink Sheet Daily
FDA advisory committee votes recommends Breo Ellipta for asthma in adults with post-approval safety study, but panel wants additional premarket efficacy and safety data for adolescents.
You may also be interested in...
LABA prescribing patterns haven’t changed despite FDA’s labeling instructions on asthma safety concerns, agency concludes.
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.